VALANX sets up SAB to advance ADC therapeutics
Biotech company VALANX has unveiled its new Scientific Advisory Board as it prepares to advance antibody-drug conjugate (ADC) therapeutics.
John Lambert has been appointed as Chair, with Morris Rosenberg and Peter de Waele serving on the board alongside him.
Lambert is a leading expert in ADC discovery and development, with particular expertise in ADC biology, payload/linker technology and translational strategies in oncology. Prior to establishing as an independent consultant, he was Executive Vice President and Distinguished Research Fellow at ImmunoGen, having previously served the company as Chief Scientific Officer and Chief Regulatory Officer.
Rosenberg joins as a biopharmaceutical consultant with over 25 years of experience in biologics development, manufacturing and commercialisation, while de Waele brings experience in immuno-oncology, advanced therapeutics, and biotech innovation.
VALANX says the newly formed board will provide independent scientific and strategic guidance, bridging the gap between research and clinical application to advance the company’s antibody-drug conjugate (ADC) programmes. This includes VLX-ADC-001, a LIV-1 targeting ADC intended for metastatic triple-negative-breast cancer, with lead candidate selection expected in June 2026.
“Establishing our SAB is an important next step and milestone for VALANX,” said Michael Lukesch, Founder and Chief Executive Officer at VALANX Biotech.
“As we advance differentiated ADC assets and our GoldenSite platform towards the clinic, the expertise of the Scientific Advisory Board will be instrumental in shaping our asset strategy and positioning within the wider ADC field. I am looking forward to working with these distinguished experts in ADC development.”
